Dr Beshir is a genomic epidemiologist with a background in Biology, Medical Parasitology and Biomedical Science.

Dr Beshir's research work focuses on understanding how malaria parasites evade drug attack (become resistant) and escape detection by rapid diagnostic tests (RDTs)and become undetectable. To achieve this, we continuously work on the development of new and fit-for-purpose molecular and genomic tools to detect and monitor these new malaria parasite population. Dr Beshir has previously worked on the development of affordable COVID-19 testing assays that can be used in Low and Middle Income Countries, and supported LMIC countries with COVID-19 vaiant detections using NGS genomics.

Dr Beshir previously worked on EDCTP-funded WANECAM project on Clinical trial of four Artemisinin Combination Therapies (ACT) in west Africa. Dr Beshir also worked on molecular evaluation of the efficacy of ACTs as well as Seasonal Malaria Chemoprevention (SMC) therapies in West Africa. In both projects, Dr Beshir worked on development of new molecular tools to monitor the emergence of drug resistance parasites to both ACTs and SMCs.

Dr Beshir is also involved in teaching both within LSHTM and externally, and supervision of MSc and PhD students. Dr Beshir is also a member of LSHTM ethics commitee and member of EDI in ITD Faculty.

Dr Beshir completed his PhD in Prof Sutherland's group.